Fc Fusion Protein Market Report mainly improves market size,and provide detailed product mapping and investigation of various market scenarios. Our expert analysts provide a thorough analysis and breakdown of the market presence of key market leaders. We strive to stay updated with the recent developments and follow the latest company news related to the industry players operating in the global Fc Fusion Protein market. This helps us to comprehensively analyze the individual standing of the companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study to help you gain the upper hand in the competition.
Increasing use of Fc fusion protein for vaccines is also expected to contribute significantly to revenue growth of the market between 2021 and 2028. Vaccination is becoming more important as the prevalence of infectious diseases rises around the globe. Increased use of Fc fusion protein for vaccines such as Filovirus vaccines is expected to boost market growth going ahead. In rabbits, mice, and monkeys, the immunogenicity of a CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein as a potential COVID-19 vaccine option was studied
Get a Free sample of the report : https://www.emergenresearch.com/request-sample/816
However, Fc fusion protein is subject to stringent regulations when it is sold or used in clinical studies, which is a key factor expected to hamper growth of the global Fc fusion protein market to some extent in the near future. In addition, side effects of recombinant Eloctate with Fc fusion protein, which is used for treating hemophilia, is a factor expected to restrain market revenue growth to some extent..
Some Key Highlights from the Report
Eye diseases segment revenue is expected to expand at a significantly rapid CAGR during the forecast period due to rising usage of Fc fusion protein for treating retinal diseases.
Biosimilar drugs segment is expected to register a significantly robust revenue growth rate over the forecast period. Fc fusion protein biosimilars have been utilized in a variety of clinical trials for cancer, chronic inflammatory disorders, HIV/AIDS, and other chronic diseases.
In vivo segment is expected to register significant growth in terms of revenue during the forecast period due to rising demand for bio-therapeutic drugs.
The market in North America is expected to account for largest revenue share over the forecast period due to rising demand for drugs based on Fc fusion protein for diabetes treatment.
Some major companies in the market report include Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Swedish Orphan Biovitrum AB, Eli Lilly and Company, Astellas Pharma Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., and 3SBio Inc.
In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. announced reaching a formal agreement, in which Pfizer would acquire Trillium, which is a clinical-stage immuno-oncology firm developing novel cancer treatments. With the inclusion of next-generation, experimental immuno-therapeutics for hematological malignancies, the acquisition would improve Pfizer's expertise in Oncology.
The report further offers a complete value chain analysis along with an analysis of the downstream buyers and upstream raw materials. The study focuses on global trends, regulatory frameworks, and macro- and micro-economic factors. The report also provides an extensive analysis of the segment and sub-segmented expected to dominate the market over the projected period. The report offers a forecast estimation of the market with regards to the analysis of the market segmentation, including product type, end-user industries, application spectrum, and other segments.
Emergen Research has segmented the global Fc fusion protein on the basis of type, therapeutic area, application, end-use, and region:
Type Outlook (Revenue, USD Billion; 2018–2028)
- Biosimilar Drugs
- Brands Drugs
Therapeutic Area Outlook (Revenue, USD Billion; 2018–2028)
- Eye Diseases
- Hemophilia
- Autoimmune Disease
- Diabetes
- Others
Application Outlook (Revenue, USD Billion; 2018–2028)
- In Vitro
- Immunohistochemistry
- Flow Cytometry
- Binding Assays
- Microarray Technologies
- In Vivo
- Bio-therapeutic Drugs
Request customization of the report: https://www.emergenresearch.com/request-for-customization/816
End-Use Outlook (Revenue, USD Billion; 2018–2028)
- Hospitals
- Ophthalmic Hospitals
- Oculoplastic Clinics
Market Taxonomy:
Chapter 1: Methodology & Scope
- Definition and forecast parameters
- Methodology and forecast parameters
- Data Sources
Chapter 2:
Executive Summary
- Business trends
- Regional trends
- Product trends
- End-use trends
Chapter 3:
Industry Insights
- Industry segmentation
- Industry landscape
- Vendor matrix
- Technological and innovation landscape
Chapter 4:
Regional Landscape
Chapter 5:
Company Profile
- Business Overview
- Financial Data
- Product Landscape
- Strategic Outlook
Key questions addressed in the report:
- What are the key factors driving the global Fc Fusion Protein market?
- Who are the key manufacturers in this market space?
- Who are the distributors, traders and dealers of this market?
- What are the market opportunities and risks affecting the performance of the vendors in the global Fc Fusion Protein market?
- What are the sales and revenue estimations for the top manufacturers in this market over the projected timeline?
Read More: https://www.emergenresearch.com/industry-report/fc-fusion-protein-market
Related Reports:
ambulatory ehr market
https://www.google.al/url?q=https://www.emergenresearch.com/industry-report/ambulatory-ehr-market
medical smart textiles market
sensors in internet of things devices market
specialty enzymes market
https://www.google.al/url?q=https://www.emergenresearch.com/industry-report/specialty-enzymes-market
tumor genomics market
https://www.google.al/url?q=https://www.emergenresearch.com/industry-report/tumor-genomics-market
wearable injectors market
in-situ hybridization market
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian